The registry aims to collect and analyse information on the antineoplastic treatment of patients with unresectable locally advanced or metastatic pancreatic cancer, treated in palliative intention (cohort 1) and patients with localized, resectable pancreatic cancer treated in neo-adjuvant or adjuvant intention (cohort 2) in daily routine practice in Germany. The registry will follow up patients for two years. It will identify common sequences of treatments used as well as changes in the treatment of the disease. Health-related quality of life will be analysed during the course of the treatment (PanLife). Based on the available data a prognostic score will be developed.

Inclusion Criteria:

• resectable or locally advanced/metastatic pancreatic cancer
• 18 years and older
• Antineoplastic treatment
• Date of consent no later than 2 weeks after start of first-line treatment

Exclusion Criteria:

• No pancreatic cancer
• Below 18 years and older
• No antineoplastic treatment
• Date of consent later than 2 weeks after start of first-line treatment

Patients with pancreatic cancer undergoing antineoplastic treatment.